Bradley Gillespie, PharmD is focused on the early development and regulation of biologics and small molecules. His core expertise is in the strategic planning and execution of Phase 1A/B clinical development programs.

He began his career as a pharmacokinetic reviewer at the U.S. Food & Drug Administration, then rose to higher levels of responsibility at Pharmacia and Amgen followed by a return to government service, leading virtual development efforts at National Center for Advancing Translational Sciences / National Institute of Health (rare and neglected disease) and the Department of Defense.

Since 2009, Brad has maintained a consulting practice offering full clinical pharmacology (to include pharmacokinetic analysis and interpretation) and early development regulatory support. Brad has regulatory expertise that includes facilitating the transition of assets from the nonclinical space, through the regulatory process. In addition to driving the strategy, these efforts include the generation of ancillary documents (Investigator's brochure, protocol, informed consent forms, CTD module 2.7 and clinical study reports). He is especially proud of his ability to leverage his development skills to generate solid, value-added protocols and clinical study reports.

In addition to his pharmaceutical pursuits, he volunteers as a Court Appointed Special Advocate and as a mentor at a homeless shelter.